PTN stock soared as much as 28% in early session on Monday after the United States Food and Drug Administration granted marketing approval for Palatin Technologies’ (NYSE:PTN) Vyleesi.
Key Development for Amag and Palatin Technologies‘Female Viagra’ or a medicine that is supposed to treat loss of sexual desire in premenopausal women has been in the works for quite some time, and despite many attempts by a range of companies, no great breakthrough has taken place thus far.
However, it all changed on Saturday when it emerged that the drug regulator in the United ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.